Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision diagnostics and radiopharmaceutical agents. The company’s radiopharmaceutical development programs include Lymphoseek Injection, a receptor-targeted small-molecule investigational radiopharmaceutical that is used in lymphatic mapping procedures, which are performed to help stage breast cancer and melanoma; and NAV4694, an F-18 radiolabeled positron emission tomography imaging agent, which is used as an aid in the diagnosis of patients with signs or symptoms of cognitive impairment, such as Alzheimer’s disease. Its radiopharmaceutical development programs also comprise NAV5001, an Iodine-123 radiolabeled single photon emission computed tomography imaging agent that is used as an aid in the diagnosis of Parkinson’s disease and other movement disorders with potential use as a diagnostic aid in dementia; and RIGScan, a radiolabeled monoclonal antibody that is developed as a diagnostic aid for use during surgery to help surgeons locate occult or metastatic cancer, primarily colorectal cancer. It has research and development agreements with University of California, AstraZeneca AB, Alseres Pharmaceuticals, Inc., and The Ohio State University. The company was formerly known as Neoprobe Corporation and changed its name to Navidea Biopharmaceuticals, Inc. in January 2012. Navidea Biopharmaceuticals, Inc. was founded in 1983 and is headquartered in Dublin, Ohio.

Key Statistics